Associated Papers
Whole-Exome Sequencing Reveals Novel Candidate Driver Mutations and Potential Druggable Mutations in Patients with High-Risk Neuroblastoma.
Nokchan N et al.
Journal of Personalized Medicine, 2024
Simulation analysis of EGFR mutation detection: Oncomine Dx target test and AmoyDx panel impact on lung cancer treatment decisions.
Hirotsu Y et al.
Scientific Reports, 2024
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
Ikeuchi H et al.
Oncogene, 2022
Analysis of single-nucleotide polymorphisms in genes associated with triple-negative breast cancer.
G V et al.
Frontiers in Genetics, 2022
Identification of PKHD1 mutations in Brain, Breast and Rectal tumors by Next Generation DNA Sequencing.
Mohammed Almehmadi D et al.
The Gulf Journal of Oncology, 2021
ErBb Family Proteins in Cholangiocarcinoma and Clinical Implications.
Jin W
Journal of Clinical Medicine, 2020
Next generation DNA sequencing of atypical choroid plexus papilloma of brain: Identification of novel mutations in a female patient by Ion Proton.
Taher MM et al.
Oncology Letters, 2019
Molecular subtype switching in early-stage gastric cancers with multiple occurrences.
Takaoka S et al.
Journal of Gastroenterology, 2019
Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing.
Kohsaka S et al.
Future Oncology (london, England), 2019
A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.
Kohsaka S et al.
Science Translational Medicine, 2017
Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma.
Kim EY et al.
Cancer Biology & Therapy, 2016
Discrimination of driver and passenger mutations in epidermal growth factor receptor in cancer.
Anoosha P et al.
Mutation Research, 2015
Structural Stability and Flexibility Direct the Selection of Activating Mutations in Epidermal Growth Factor Receptor Kinase.
Paladino A et al.
Journal of Chemical Information and Modeling, 2015
Lack of mutations in protein tyrosine kinase domain coding exons 19 and 21 of the EGFR gene in oral squamous cell carcinomas.
Mehta DT et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2014
Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
Wu JY et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011
The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors.
Stehr H et al.
Molecular Cancer, 2011
Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer.
Peraldo-Neia C et al.
Bmc Cancer, 2011
The energy landscape analysis of cancer mutations in protein kinases.
Dixit A et al.
Plos One, 2011
Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer.
Zhang X et al.
Journal of Medical Genetics, 2007
Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer.
Shih JY et al.
International Journal of Cancer, 2006
High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.
Huang SF et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2004